



Hiranandani  
HOSPITAL

(A Fortis Network Hospital)

Hiranandani Fortis Hospital  
Mini Seashore Road,  
Sector 10 - A, Vashi,  
Navi Mumbai - 400 703.  
Tel. : +91-22-3919 9222  
Fax : +91-22-3919 9220/21  
Email : vashi@vashihospital.com

### BMI CHART

Date: 11/11/2025

Name: Raju Saibsat Age: 39 yrs Sex: M / F

BP: 130/90 Height (cms): 165 cm Weight (kgs): 83.5 kg BMI: \_\_\_\_\_  
SP02 100% P - 63 bpm

WEIGHT lbs	130	135	140	145	150	155	160	165	170	175	180	185	190	195	200	205	210	215		
kgs	45.9	47.7	49.5	51.3	53.1	54.9	56.7	58.5	60.3	62.1	63.9	65.7	67.5	69.3	71.1	72.9	74.7	76.5		
HEIGHT in/cm	Underweight				Healthy				Overweight				Obese				Extremely Obese			
5'0" - 151.4	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36		
5'1" - 154.9	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35		
5'2" - 157.4	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35		
5'3" - 160.0	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34		
5'4" - 162.5	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34		
5'5" - 165.1	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33		
5'6" - 167.6	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33		
5'7" - 170.1	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32		
5'8" - 172.7	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32		
5'9" - 175.2	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31		
5'10" - 177.8	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31		
5'11" - 180.3	14	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30		
6'0" - 182.8	13	14	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29		
6'1" - 185.4	13	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29		
6'2" - 187.9	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29		
6'3" - 190.5	12	13	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28		
6'4" - 193.0	12	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28		

Doctors Notes:

---

---

---

---

---

---

---

---

Signature



UHID	12814872	Date	11/11/2023
Name	Mr.Raju Shirsat	Sex	M
OPD	Ophthal	Age	39
		Health Check-up	

Abi. No

hwa no

Drug allergy: -> Not know  
 Sys illness: -> .

Habit -> NO

Uick -> Rg Glc.  
 -> G Glc.

Rf -> Rg Pheno Glc  
 -> G Pheno Glc

NR -> Rg No  
 -> G No

FAD -> Rg 14.8  
 -> G 15.8

*[Handwritten Signature]*

\* P6h-Tens -> (1) (1) (1)  
 6 needs



UHID	12814872	Date	11/11/2023	
Name	Mr. Raju Shirsat	Sex	M	Age 39
OPD	Dental	Health Check-up		

1) Graveling

Drug allergy:  
 Sys illness:

Missing

1)

2) Isth + f

3) calu + f

Dr. 1 ① Impacted tooth

2) other teeth + 1st  
 3) scaling

→ OPD - 8am

Dr. V. V. Dhanraj

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD  
FORTIS HOSPITAL # VASHI,  
MUMBAI 440001

ACCESSION NO : 0022WK002206

PATIENT ID : FH.12814872

CLIENT PATIENT ID: UID:12814872

ABHA NO :

AGE/SEX : 39 Years Male

DRAWN : 11/11/2023 10:16:00

RECEIVED : 11/11/2023 10:16:34

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

UID:12814872 REQNO-1605165

CORP-OPD

BILLNO-1501230PCR064300

BILLNO-1501230PCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## HAEMATOLOGY - CBC

## CBC-5, EDTA WHOLE BLOOD

## BLOOD COUNTS, EDTA WHOLE BLOOD

HEMOGLOBIN (HB) METHOD : SLS METHOD	14.7	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD : HYDRODYNAMIC FOCUSING	5.08	4.5 - 5.5	mil/ $\mu$ L
WHITE BLOOD CELL (WBC) COUNT METHOD : FLUORESCENCE FLOW CYTOMETRY	8.56	4.0 - 10.0	thou/ $\mu$ L
PLATELET COUNT METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION	319	150 - 410	thou/ $\mu$ L

## RBC AND PLATELET INDICES

HEMATOCRIT (PCV) METHOD : CUMULATIVE PULSE HEIGHT DETECTION METHOD	44.4	40.0 - 50.0	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD : CALCULATED PARAMETER	87.4	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER	28.9	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC) METHOD : CALCULATED PARAMETER	33.1	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : CALCULATED PARAMETER	12.1	11.6 - 14.0	%
MENTZER INDEX METHOD : CALCULATED PARAMETER	17.2		
MEAN PLATELET VOLUME (MPV) METHOD : CALCULATED PARAMETER	9.2	6.8 - 10.9	fL

## WBC DIFFERENTIAL COUNT



Dr. Akshay Dhotre, MD  
(Reg.no. MMC 2019/09/6377)  
Consultant Pathologist

Page 1 Of 17



View Details



View Report

## PERFORMED AT :

Agilus Diagnostics Ltd.  
Hiranandani Hospital-Vashi, Mini Senshore Road, Sector 10,  
Navi Mumbai, 400703  
Maharashtra, India  
Tel : 022-39199222, 022-49723322,  
CIN - U74899PB1995PLC045956  
Email : -



Patient Ref. No. 2200000884349

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD  
FORTIS HOSPITAL # VASHI,  
MUMBAI 440001

ACCESSION NO : 0022WK002206

PATIENT ID : FH.12814872

CLIENT PATIENT ID: UID:12814872

ABHA NO :

AGE/SEX : 39 Years Male

DRAWN : 11/11/2023 10:16:00

RECEIVED : 11/11/2023 10:16:34

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

UID:12814872 REQNO-1605165

CORP-OPD

BILLNO-1501230PCR064300

BILLNO-1501230PCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
NEUTROPHILS		44	40.0 - 80.0	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
LYMPHOCYTES		42 High	20.0 - 40.0	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
MONOCYTES		7	2.0 - 10.0	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
EOSINOPHILS		7 High	1 - 6	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
BASOPHILS		0	0 - 2	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
ABSOLUTE NEUTROPHIL COUNT		3.77	2.0 - 7.0	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT		3.60 High	1.0 - 3.0	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT		0.60	0.2 - 1.0	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT		0.60 High	0.02 - 0.50	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT		0 Low	0.02 - 0.10	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		1.0		
METHOD : CALCULATED				

## MORPHOLOGY

RBC

METHOD : MICROSCOPIC EXAMINATION

PREDOMINANTLY NORMOCYTIC NORMOCHROMIC

WBC

METHOD : MICROSCOPIC EXAMINATION

NORMAL MORPHOLOGY

PLATELETS

METHOD : MICROSCOPIC EXAMINATION

ADEQUATE


Dr. Akshay Dhotre, MD  
(Reg.no. HMC 2019/09/6377)  
Consultant Pathologist

Page 2 Of 17



View Details



View Report

## PERFORMED AT :

Agilus Diagnostics Ltd.  
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
Navi Mumbai, 400703  
Maharashtra, India  
Tel : 022-39199222, 022-49723322,  
CDN - U74099PB1995PLC045956  
Email : -

  
Patient Ref. No. 22000000884349

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD  
FORTIS HOSPITAL # VASHI,  
MUMBAI 440001

ACCESSION NO : 0022WK002206

PATIENT ID : FH.12814872

CLIENT PATIENT ID: UID:12814872

ABHA NO :

AGE/SEX : 39 Years Male

DRAWN : 11/11/2023 10:16:00

RECEIVED : 11/11/2023 10:16:34

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

UID:12814872 REQNO-1605165

CORP-OPD

BILLNO-150123OPCR064300

BILLNO-150123OPCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## Interpretation(s)

RBC AND PLATELET INDICES-Mentzer Index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504  
This ratio element is a calculated parameter and out of NABL scope.



Dr. Akshay Dhotre, MD  
(Reg.no. MMC 2019/09/6377)  
Consultant Pathologist

Page 3 Of 17



View Details



View Report

## PERFORMED AT :

Agilus Diagnostics Ltd.  
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
Navi Mumbai, 400703  
Maharashtra, India  
Tel : 022-39199222,022-49723322,  
CIN - U74099PB1995PLC045956  
Email : -



Patient Ref. No. 22000000884349

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

ACCESSION NO : 0022WK002206

PATIENT ID : FH.12814872

CLIENT PATIENT ID: UID:12814872

ABHA NO :

AGE/SEX : 39 Years Male

DRAWN : 11/11/2023 10:16:00

RECEIVED : 11/11/2023 10:16:34

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

UID:12814872 REQNO-1605165

CORP-OPD

BILLNO-150123OPCR064300

BILLNO-150123OPCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## HAEMATOLOGY

## ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R	08	0 - 14	mm at 1 hr
-------	----	--------	------------

METHOD : WESTERGREN METHOD

## GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C	5.3	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
-------	-----	--	---

METHOD : HB VARIANT (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG)	105.4	< 116.0	mg/dL
--------------------------------	-------	---------	-------

METHOD : CALCULATED PARAMETER

## Interpretation(s)

## ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays, fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

## TEST INTERPRETATION

**Increase in:** Infections, Vasculitis, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy ESR in first trimester is 0-45 mm/hr (52 if anemic) and in second trimester (0-70 mm/hr (95 if anemic). ESR returns to normal 4th week post partum.

**Decreased in:** Polycythemia vera, Sickle cell anemia

## LIMITATIONS

**False elevated ESR :** Increased fibrinogen, Drugs (Vitamin A, Dextran etc), Hypercholesterolemia

**False Decreased :** Polycythemia, (Sickle Cells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)



Page 4 Of 17

Dr. Akshay Dhotre, MD  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist



View Details



View Report

## PERFORMED AT :

Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222, 022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -



Patient Ref. No. 2200000088-1349

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD  
FORTIS HOSPITAL # VASHI,  
MUMBAI 440001

ACCESSION NO : 0022WK002206

PATIENT ID : FH.12814872

CLIENT PATIENT ID: UID:12814872

ABHA NO :

AGE/SEX : 39 Years Male

DRAWN : 11/11/2023 10:16:00

RECEIVED : 11/11/2023 10:16:34

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

UID:12814872 REQNO-1605165

CORP-OPD

BILLNO-1501230PCR064300

BILLNO-1501230PCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition, Edited by S. Sokolic; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition, GLYCOSYLATED HEMOGLOBIN(HbA1c), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dL to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as  $eAG (mg/dL) = 28.7 * HbA1c - 46.7$

## HbA1c Estimation can get affected due to :

1. Shortened erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will likely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
2. Vitamin C & E are reported to likely lower test results (possibly by inhibiting glycation of hemoglobin).
3. Iron deficiency anemia is reported to increase test results. Hyperglycaemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.
4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Heterozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate pathway (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Page 5 Of 17

Dr. Akshay Dhotre, MD  
(Reg.no. MMC 2019/09/6377)  
Consultant Pathologist




View Details



View Report

## PERFORMED AT :

Agilus Diagnostics Ltd.  
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
Navi Mumbai, 400703  
Maharashtra, India  
Tel : 022-39199222, 022-49723322,  
CIN - U74899PB1995PLC045956  
Email : -



Patient Ref. No. 22000000884349




**PATIENT NAME : MR.RAJU BHARAT SHIRSAT**
**REF. DOCTOR :**
**CODE/NAME & ADDRESS : C000045507**

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

**ACCESSION NO : 0022WK002206**
**PATIENT ID : PH.12814872**
**CLIENT PATIENT ID: UID:12814872**
**ASHA NO :**
**AGE/SEX : 39 Years Male**
**DRAWN : 11/11/2023 10:16:00**
**RECEIVED : 11/11/2023 10:16:34**
**REPORTED : 11/11/2023 14:10:49**
**CLINICAL INFORMATION :**

 UID:12814872 REQNO-1605165  
 CORP-OPD  
 BILLNO-150123OPCR064300  
 BILLNO-150123OPCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**IMMUNOHAEMATOLOGY**
**ABO GROUP & RH TYPE, EDTA WHOLE BLOOD**

ABO GROUP	TYPE B
METHOD : TUBE AGGLUTINATION	
RH TYPE	POSITIVE
METHOD : TUBE AGGLUTINATION	

**Interpretation(s)**

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A, B, O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Page 6 Of 17

Dr. Akshay Dhotra, MD  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist



View Details



View Report

**PERFORMED AT :**

 Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222,022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -


Patient Ref. No. 2200000884348

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD  
FORTIS HOSPITAL # VASHI,  
MUMBAI 440001

ACCESSION NO : 0022WK002206

PATIENT ID : FH.12814872

CLIENT PATIENT ID: UID:12814872

ABHA NO :

AGE/SEX : 39 Years Male

DRAWN : 11/11/2023 10:16:00

RECEIVED : 11/11/2023 10:16:34

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

UID:12814872 REQNO-1605165

CORP-OPD

BILLNO-150123OPCR064300

BILLNO-150123OPCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## BIOCHEMISTRY

## LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.41	0.2 - 1.0	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, DIRECT	0.09	0.0 - 0.2	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, INDIRECT	0.32	0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN	7.4	6.4 - 8.2	g/dL
METHOD : BIURET			
ALBUMIN	3.8	3.4 - 5.0	g/dL
METHOD : BCP DYE BINDING			
GLOBULIN	3.6	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.1	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	18	15 - 37	U/L
METHOD : UV WITH PSP			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	29	< 45.0	U/L
METHOD : UV WITH PSP			
ALKALINE PHOSPHATASE	103	30 - 120	U/L
METHOD : PNPP-ANP			
GAMMA GLUTAMYL TRANSFERASE (GGT)	35	15 - 85	U/L
METHOD : GAMMA GLUTAMYL CARBOXY ANITROANILIDE			
LACTATE DEHYDROGENASE	67 Low	85 - 227	U/L
METHOD : LACTATE -PYRUVATE			

## GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)	96	Normal : < 100 Pre-diabetes: 100-125 Diabetes: >=126	mg/dL
---------------------------	----	--	-------

METHOD : HEXOKINASE



Dr. Akshay Dhotre, MD  
(Reg.no. MMC 2019/09/6377)  
Consultant Pathologist

Page 7 Of 17



View Details



View Report

## PERFORMED AT :

Agilus Diagnostics Ltd.  
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
Navi Mumbai, 400703  
Maharashtra, India  
Tel : 022-39199222, 022-49723322,  
CIN - U74999PB1995PLC045956  
Email : -



Patient Ref. No. 22000000884349

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

ACCESSION NO : 0022WK002206

 PATIENT ID : PH.12814872  
 CLIENT PATIENT ID: UID:12814872  
 ABHA NO :

AGE/SEX : 39 Years Male

 DRAWN : 11/11/2023 10:16:00  
 RECEIVED : 11/11/2023 10:16:34  
 REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

 UID:12814872 REQNO-1605165  
 CORP-OPD  
 BILLNO-150123OPCR064300  
 BILLNO-150123OPCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## KIDNEY PANEL - 1

## BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN METHOD : UREASE - UV	14	6 - 20	mg/dL
---	----	--------	-------

## CREATININE EGFR- EPI

CREATININE METHOD : ALKALINE PICRATE KINETIC JAFFES	0.92	0.90 - 1.30	mg/dL
AGE	39		years
GLOMERULAR FILTRATION RATE (MALE) METHOD : CALCULATED PARAMETER	108.52	Refer Interpretation Below	mL/min/1.73m <sup>2</sup>

## BUN/CREAT RATIO

BUN/CREAT RATIO METHOD : CALCULATED PARAMETER	15.22 High	5.00 - 15.00	
--	------------	--------------	--

## URIC ACID, SERUM

URIC ACID METHOD : URICASE UV	5.1	3.5 - 7.2	mg/dL
----------------------------------	-----	-----------	-------

## TOTAL PROTEIN, SERUM

TOTAL PROTEIN METHOD : BIURET	7.4	6.4 - 8.2	g/dL
----------------------------------	-----	-----------	------



Page 8 Of 17

 Dr. Akshay Dhotre, MD  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist


View Details



View Report

## PERFORMED AT :

 Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222, 022-49723322,  
 CIN - U74809PB1995PLC045956  
 Email : -


Patient Ref. No. 22000000884349

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

ACCESSION NO : 0022WK002206

PATIENT ID : FH.12814872

CLIENT PATIENT ID: USD:12814872

ABHA NO :

AGE/SEX : 39 Years Male

DRAWN : 11/11/2023 10:16:00

RECEIVED : 11/11/2023 10:16:34

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

 UID:12814872 REQNO-1605165  
 CORP-OPD  
 BILLNO-150123OPCR064300  
 BTLLNO-150123OPCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## ALBUMIN, SERUM

ALBUMIN

3.8

3.4 - 5.0

g/dL

METHOD : BCP DYE BINDING

## GLOBULIN

GLOBULIN

3.6

2.0 - 4.1

g/dL

METHOD : CALCULATED PARAMETER

## ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM

138

136 - 145

mmol/L

METHOD : ISE INDIRECT

POTASSIUM, SERUM

5.07

3.50 - 5.10

mmol/L

METHOD : ISE INDIRECT

CHLORIDE, SERUM

103

98 - 107

mmol/L

METHOD : ISE INDIRECT

## Interpretation(s)

## Interpretation(s)

## LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstructive and hepatic), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease. Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.



 Dr. Akshay Dhotre, MD  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist

Page 9 Of 17



View Details



View Report

## PERFORMED AT :

 Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222, 022-49723322,  
 CEN - U74899PB1995PLC045956  
 Email : -


Patient Ref. No. 22000000884349

**PATIENT NAME : MR.RAJU BHARAT SHIRSAT**
**REF. DOCTOR :**
**CODE/NAME & ADDRESS : C000045507**
**FORTIS VASHI-CHC -SPLZD  
FORTIS HOSPITAL # VASHI,  
MUMBAI 440001**
**ACCESSION NO : 0022WK002206**
**PATIENT ID : FH\_12814872**
**CLIENT PATIENT ID: UID:12814872**
**ABHA NO :**
**AGE/SEX :39 Years Male**
**DRAWN :11/11/2023 10:16:00**
**RECEIVED : 11/11/2023 10:16:34**
**REPORTED :11/11/2023 14:10:49**
**CLINICAL INFORMATION :**
**UID:12814872 REQNO-1605165**
**CORP-OPD**
**BILLNO-150123OPCR064300**
**BILLNO-150123OPCR064300**

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**AST** is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

**ALP** is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatemia, Malnutrition, Protein deficiency, Wilson's disease.

**GGT** is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

**Total Protein** also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burn, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

**Albumin** is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (Hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burn, hemodialysis, increased vascular permeability or decreased hepatic clearance, malnutrition and wasting etc.

**GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and that no glucose is excreted in the urine.

**Increased in:** Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%), Drugs: corticosteroids, phenytoin, estrogen, thiazides.

**Decreased in :** Pancreatic islet cell disease with increased insulin, Insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia). Drugs: insulin, ethanol, propofol, sulfonamides, tolbutamide, and other oral hypoglycemic agents.

**NOTE:** While random serum glucose levels correlate with home glucose monitoring results (usually mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycaemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased Insulin response & sensitivity etc.

**BLOOD UREA NITROGEN (BUN), SERUM-** Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Corioid, Dehydration, CHF failure), Renal failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

**Causes of decreased level include** Liver disease, STADH.

**CREATININE EGFR- EPI-** Kidney disease outcomes quality initiative (KDIGO) guidelines state that estimation of GFR is the best overall indices of the Kidney function.

- It gives a rough measure of number of functioning nephrons. Reduction in GFR implies progression of underlying disease.

- The GFR is a calculation based on serum creatinine test.

- Creatinine is mainly derived from the metabolism of creatine in muscle, and its generation is proportional to the total muscle mass. As a result, mean creatinine generation is higher in men than in women, in younger than in older individuals, and in blacks than in whites.

- Creatinine is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate.

- When kidney function is compromised, excretion of creatinine decreases with a consequent increase in blood creatinine levels. With the creatinine test, a reasonable estimate of the actual GFR can be determined.

- This equation takes into account several factors that impact creatinine production, including age, gender, and race.

- CKD EPI (Chronic kidney disease epidemiology collaboration) equation performed better than MDRD equation especially when GFR is high (>60 ml/min per 1.73m2). This formula has less bias and greater accuracy which helps in early diagnosis and also reduces the rate of false positive diagnosis of CKD.

**References:**

National Kidney Foundation (NKF) and the American Society of Nephrology (ASN).

Estimated GFR Calculated Using the CKD-EPI equation-<https://testguide.nlm.nih.gov/guide/egfr>

Ghuman JK, et al. Impact of Removing Race Variable on CKD Classification Using the Creatinine-Based 2021 CKD-EPI Equation. *Kidney Med* 2022, 4:100471. 35756325

Harrison's Principles of Internal Medicine, 21st ed. pg 62 and 334

**URIC ACID, SERUM-** Causes of Increased levels:- Dietary (High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Leach nyhan syndrome, Type 2 DM, Metabolic syndrome. Causes of decreased levels:- Low Zinc intake, OCP, Multiple Sclerosis

**TOTAL PROTEIN, SERUM-** is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

**Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease.



**Dr. Akshay Dhote, MD**  
(Reg.no. MMC 2019/09/6377)  
Consultant Pathologist

Page 10 Of 17



View Details



View Report

**PERFORMED AT :**

Agilus Diagnostics Ltd.  
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
Navi Mumbai, 400703  
Maharashtra, India  
Tel : 022-35199222, 022-49723322,  
CIN - U74899PB1995PLC045956  
Email :-



Patient Ref. No. 2200000884349

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

ACCESSION NO : 0022WK002206

PATIENT ID : FH.12814872

CLIENT PATIENT ID: UID:12814872

ABHA NO :

AGE/SEX : 39 Years Male

DRAWN : 11/11/2023 10:16:00

RECEIVED : 11/11/2023 10:16:34

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

UID:12814872 REQNO-1605165

CORP-OPD

BILLNO-1501230PCR064300

BILLNO-1501230PCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemolysis, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.



Dr. Akshay Dhotre, MD  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist

Page 11 Of 17



View Details



View Report

## PERFORMED AT :

Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222, 022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -



Patient Ref. No. 22000000884349

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD  
FORTIS HOSPITAL # VASHI,  
MUMBAI 440001

ACCESSION NO : 0022WK002206

PATIENT ID : FH.12814872

CLIENT PATIENT ID: UID:12814872

ABHA NO : 1

AGE/SEX : 39 Years Male

DRAWN : 11/11/2023 10:16:00

RECEIVED : 11/11/2023 10:16:34

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

UID:12814872 REQNO-1605165  
CORP-OPD  
BILLNO-150123OPCR064300  
BILLNO-150123OPCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## BIOCHEMISTRY - LIPID

## LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL	252 High	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
--------------------	----------	--	-------

METHOD : ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES	122	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
---------------	-----	---	-------

METHOD : ENZYMATIC ASSAY

HDL CHOLESTEROL	50	< 40 Low >/=60 High	mg/dL
-----------------	----	------------------------	-------

METHOD : DIRECT MEASURE - PEG

LDL CHOLESTEROL, DIRECT	174 High	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
-------------------------	----------	--	-------

METHOD : DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT

NON HDL CHOLESTEROL	202 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
---------------------	----------	--	-------

METHOD : CALCULATED PARAMETER

VERY LOW DENSITY LIPOPROTEIN	24.4	</= 30.0	mg/dL
------------------------------	------	----------	-------

METHOD : CALCULATED PARAMETER

CHOL/HDL RATIO	5.0 High	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
----------------	----------	--	--

METHOD : CALCULATED PARAMETER



Dr. Akshay Dhotre, MD  
(Reg.no. MMC 2019/09/6377)  
Consultant Pathologist

Page 12 Of 17




View Details



View Report

## PERFORMED AT :

Agilus Diagnostics Ltd.  
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
Navi Mumbai, 400703  
Maharashtra, India  
Tel : 022-39199222, 022-49723322,  
CIN - U74899PB1995PLC045956  
Email : -



Patient Ref. No. 2200000884349

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

ACCESSION NO : 0022WK002206

PATIENT ID : FH.12814872

CLIENT PATIENT ID: UID:12814872

ABHA NO : 1

AGE/SEX : 39 Years Male

DRAWN : 11/11/2023 10:16:00

RECEIVED : 11/11/2023 10:16:34

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

 UID:12814872 REQNO-1605165  
 CORP-OPD  
 BILLNO-150123OPCR064300  
 BILLNO-150123OPCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

LDL/HDL RATIO

3.5 High

 0.5 - 3.0 Desirable/Low Risk  
 3.1 - 6.0 Borderline/Moderate  
 Risk  
 >6.0 High Risk

METHOD : CALCULATED PARAMETER

## Interpretation(s)



 Dr. Akshay Dhotra, MD  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist

Page 13 Of 17




View Details



View Report

## PERFORMED AT :

 Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222, 022-49723322,  
 CIN - U74299PB1995PLC045956  
 Email : -


Patient Ref. No. 22000000884349



PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

 FORTIS VASHI-CHC -SPLZD  
 FORTIS HOSPITAL # VASHI,  
 MUMBAI 440001

ACCESSION NO : 0022WK002206

PATIENT ID : FH.12814872

CLIENT PATIENT ID: UID:12814872

ABHA NO :

AGE/SEX : 39 Years Male

DRAWN : 11/11/2023 10:16:00

RECEIVED : 11/11/2023 10:16:34

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

 UID:12814872 REQNO-1605165  
 CORP-OPD  
 BILLNO-1501230PCR064300  
 BILLNO-1501230PCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## CLINICAL PATH - URINALYSIS

## KIDNEY PANEL - 1

## PHYSICAL EXAMINATION, URINE


COLOR	PALE YELLOW
METHOD : PHYSICAL	
APPEARANCE	CLEAR
METHOD : VISUAL	

## CHEMICAL EXAMINATION, URINE

PH	6.0	4.7 - 7.5
METHOD : REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD		
SPECIFIC GRAVITY	1.020	1.003 - 1.035
METHOD : REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)		
PROTEIN	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE		
GLUCOSE	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD		
KETONES	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE		
BLOOD	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN		
BILIRUBIN	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT		
UROBILINOGEN	NORMAL	NORMAL
METHOD : REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRLICH REACTION)		
NITRITE	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE		
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY		



 Dr. Akshay Dhotre, MD  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist



 Dr. Rekha Nair, MD  
 (Reg No. MMC 2001/06/2354)  
 Microbiologist

Page 14 Of 17



View Details



View Report

## PERFORMED AT :

 Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Senshore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222, 022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -


Patient Ref. No. 22000000884349

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

ACCESSION NO : 0022WK002206

AGE/SEX : 39 Years Male

FORTIS VASHI-CHC -SPLZD

PATIENT ID : FH.12814872

DRAWN : 11/11/2023 10:16:00

FORTIS HOSPITAL # VASHI,

CLIENT PATIENT ID: UID:12814872

RECEIVED : 11/11/2023 10:16:34

MUMBAI 440001

ABHA NO :

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

UID:12814872 REQNO-1605165

CORP-OPD

BILLNO-150123OPCR064300

BILLNO-150123OPCR064300


Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION			
PUS CELL (WBC'S)	0-1	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
EPITHELIAL CELLS	1-2	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
CASTS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
CRYSTALS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
YEAST	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
REMARKS	URINARY MICROSCOPIC EXAMINATION DONE ON URINARY CENTRIFUGED SEDIMENT		



Dr. Akshay Dhotre, MD  
(Reg.no. MMC 2019/09/6377)  
Consultant Pathologist



Dr. Rekha Nair, MD  
(Reg No. MMC 2001/06/2354)  
Microbiologist




View Details



View Report

## PERFORMED AT :

Agilus Diagnostics Ltd,  
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
Navi Mumbai, 400703  
Maharashtra, India  
Tel : 022-35199222, 022-49723322,  
CIN - U74899PB1995PLC045956  
Email : -



Patient Ref. No. 22000000884342

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : CG00045507

ACCESSION NO : 0022WK002206

AGE/SEX : 39 Years Male

FORTIS VASHI-CHC -SPLZD

PATIENT ID : FH.12814872

DRAWN : 11/11/2023 10:16:00

FORTIS HOSPITAL # VASHI,

CLIENT PATIENT ID: UID:12814872

RECEIVED : 11/11/2023 10:16:34

MUMBAI 440001

ABHA NO :

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

UID:12814872 REQNO-1605165

CORP-OPD

BILLNO-150123OPCR064300

BILLNO-150123OPCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## SPECIALISED CHEMISTRY - HORMONE

## THYROID PANEL, SERUM

T3	132.9	80.0 - 200.0	ng/dL
METHOD : ELECTROCHEMILUMINESCENCE IMMUNOASSAY, COMPETITIVE PRINCIPLE			
T4	8.83	5.10 - 14.10	µg/dL
METHOD : ELECTROCHEMILUMINESCENCE IMMUNOASSAY, COMPETITIVE PRINCIPLE			
TSH (ULTRASENSITIVE)	2.100	0.270 - 4.200	µIU/mL
METHOD : ELECTROCHEMILUMINESCENCE SANDWICH IMMUNOASSAY			

## Interpretation(s)



Dr. Akshay Dhotre, MD  
(Reg.no. MMC 2019/09/6377)  
Consultant Pathologist



View Details



View Report

## PERFORMED AT :

Agilus Diagnostics Ltd.  
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
Navi Mumbai, 400703  
Maharashtra, India  
Tel : 022-39199222, 022-49723322,  
CIN - U74999PB1995PLC045956  
Email : -



Patient Ref. No. 22000000884149

PATIENT NAME : MR.RAJU BHARAT SHIRSAT

REF. DOCTOR :

CODE/NAME &amp; ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD  
FORTIS HOSPITAL # VASHI,  
MUMBAI 440001

ACCESSION NO : 0022WK002206

PATIENT ID : FH.12814872

CLIENT PATIENT ID: UID:12814872

ABHA NO :

AGE/SEX : 39 Years Male

DRAWN : 11/11/2023 10:16:00

RECEIVED : 11/11/2023 10:16:34

REPORTED : 11/11/2023 14:10:49

## CLINICAL INFORMATION :

UID:12814872 REQNO-1605165

CORP-OPD

BILLNO-150123OPCR064300

BILLNO-150123OPCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## SPECIALISED CHEMISTRY - TUMOR MARKER

## PROSTATE SPECIFIC ANTIGEN, SERUM

PROSTATE SPECIFIC ANTIGEN	0.863	0.0 - 1.4	ng/mL
---------------------------	-------	-----------	-------

METHOD : ELECTROCHEMILUMINESCENCE SANDWICH IMMUNOASSAY

## Interpretation(s)

PROSTATE SPECIFIC ANTIGEN, SERUM-- PSA is detected in the male patients with normal, benign hyperplastic and malignant prostate tissue and in patients with prostatitis.

- PSA is not detected (or detected at very low levels) in the patients without prostate tissue (because of radical prostatectomy or cystoprostatectomy) and also in the female patients.
- It is a suitable marker for monitoring of patients with Prostate Cancer and it is better to be used in conjunction with other diagnostic procedures.
- Serial PSA levels can help determine the success of prostatectomy and the need for further treatment, such as radiation, endocrine or chemotherapy and useful in detecting residual disease and early recurrence of tumor.
- Elevated levels of PSA can be also observed in the patients with non-malignant diseases like Prostatitis and Benign Prostatic Hyperplasia.
- Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA (false positive) levels persisting up to 3 weeks.
- As per American urological guidelines, PSA screening is recommended for early detection of prostate cancer above the age of 40 years. Following Age specific reference range can be used as a guide lines.
- Measurement of total PSA alone may not clearly distinguish between benign prostatic hyperplasia (BPH) from cancer, this is especially true for the total PSA values between 4-10 ng/mL.
- Total PSA values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations. Recommended follow up on same platform as patient result can vary due to differences in assay method and reagent specificity.

## References-

1. Burts CA, Ashwood ER, Bruns DE, Telfz textbook of clinical chemistry and Molecular Diagnostics. 4th edition.
2. Williamson MA, Snyder LM. Willich's interpretation of diagnostic tests. 9th edition.

\*\*End Of Report\*\*

Please visit [www.agilusdiagnostics.com](http://www.agilusdiagnostics.com) for related Test Information for this accession


Dr. Akshay Dhotre, MD  
(Reg.no. MMC 2019/09/6377)  
Consultant Pathologist

Page 17 Of 17




View Details



View Report

## PERFORMED AT :

Agilus Diagnostics Ltd.  
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
Navi Mumbai, 400703  
Maharashtra, India  
Tel : 022-39199222, 022-49723322,  
CIN - U74899PB1995PLC045956  
Email : -



Patient Ref. No. 22000000884349

 <b>PATIENT NAME : MR.RAJU BHARAT SHIRSAT</b> <b>CODE NAME &amp; ADDRESS : C000045507</b> FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001	<b>REF. DOCTOR :</b>		
	<b>ACCESSION NO : 0022WK002264</b> <b>PATIENT ID : FH.12814872</b> <b>CLIENT PATIENT ID: UID:12814872</b> <b>ABHA NO :</b>	<b>AGE/SEX : 39 Yrs</b> <b>DRAWN : 11/11/2023 12:53:00</b> <b>RECEIVED : 11/11/2023 12:53:03</b> <b>REPORTED : 11/11/2023 13:57:53</b>	

**CLINICAL INFORMATION :**

UID:12814872 REQNO-1605165  
 CORP-OPD  
 BILLNO-150123OPCR064300  
 BILLNO-150123OPCR064300

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**BIOCHEMISTRY****GLUCOSE, POST-PRANDIAL, PLASMA**

PPBS(POST PRANDIAL BLOOD SUGAR)	110	70 - 140	mg/dL
METHOD : HEXOKINASE			

**Interpretation(s)**

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c

**\*\*End Of Report\*\***

Please visit [www.agilusdiagnostics.com](http://www.agilusdiagnostics.com) for related Test Information for this accession



**Dr. Akshay Dhotre, MD**  
 (Reg.no. MMC 2019/09/6377)  
 Consultant Pathologist

Page 1 Of 1



View Details



View Report

**PERFORMED AT :**

Agilus Diagnostics Ltd.  
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,  
 Navi Mumbai, 400703  
 Maharashtra, India  
 Tel : 022-39199222,022-49723322,  
 CIN - U74899PB1995PLC045956  
 Email : -



Patient Ref. No. 22000000884402

Rate 72 . Sinus rhythm.....normal P axis, V-rate 50- 99  
 PR 128 . RSR' in V1 or V2, probably normal variant.....small R' only  
 QRS 83 . ST elev, probable normal early repol pattern.....ST elevation, age<55  
 QT 373 . Baseline wander in lead(s) V2  
 QTc 409

*Sinus Rhythm  
 No significant abnormalities*


--AXIS--

P 58  
 QRS 17  
 T 21

12 Lead; Standard Placement

- OTHERWISE NORMAL ECG -

Unconfirmed Diagnosis



Device: Speed: 25 mm/sec Limb: 10 mm/mV Chest: 10.0 mm/mV  
 P 50- 0.50-100 Hz W 100B CL P?

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220

Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823

GST IN : 27AA8CH5854D1ZG

PAN NO : AABCH5854D



DEPARTMENT OF RADIOLOGY

Date: 11/Nov/2023

Name: Mr. Raju Bharat Shirsat

Age | Sex: 39 YEAR(S) | Male

Order Station : FO-OPD

Bed Name :

UHID | Episode No : 12814872 | 65310/23/1501

Order No | Order Date: 1501/PN/OP/2311/135827 | 11-Nov-2023

Admitted On | Reporting Date : 11-Nov-2023 11:48:56

Order Doctor Name : Dr.SELF .

X-RAY-CHEST- PA

Findings:

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Bony thorax is unremarkable.

DR. YOGINI SHAH  
DMRD., DNB. (Radiologist)



Patient Name	: Raju Bharat Shirsat	Patient ID	: 12814872
Sex / Age	: M / 39Y 6M 12D	Accession No.	: PHC.6919946
Modality	: US	Scan DateTime	: 11-11-2023 23:24:13
IPID No	: 65310/23/1501	ReportDatetime	: 11-11-2023 11:50:29

### USG – WHOLE ABDOMEN

**LIVER** is normal in size and echogenicity. No IHBR dilatation. A well-defined hyperechoic lesion of size 1 x 0.9 cm is seen in segment IV – likely hemangioma.

A 5.5 mm sized calcified granuloma is seen in segment VI.

Portal vein appears normal in caliber.

**GALL BLADDER** is physiologically distended. Gall bladder reveals normal wall thickness. No evidence of calculi in gall bladder. No evidence of pericholecystic collection.

**CBD** appears normal in caliber.

**SPLEEN** is normal in size and echogenicity.

**BOTH KIDNEYS** are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.

Right kidney measures 11.3 x 4.9 cm.

Left kidney measures 10.8 x 5.5 cm.

**PANCREAS:** Head of pancreas is visualised and appears normal. Rest of the pancreas is obscured.

**URINARY BLADDER** is normal in capacity and contour. Bladder wall is normal in thickness. No evidence of intravesical calculi.

**PROSTATE** is normal in size & echogenicity. It measures ~ 20.5 cc in volume.

No evidence of ascites.

A subcutaneous lipoma is seen in right lumbar region lateral abdominal wall, measuring 4.0 x 1.8 cm.

### Impression:

- Hepatic hemangioma as described. *Recommended Triple phase CECT abdomen & pelvis if clinically indicated.*
- Subcutaneous lipoma as described.

DR. CHETAN KHADKE

M.D. (Radiologist)